Proteomics International Laboratories (ASX:PIQ) received a patent from the Canadian Patent Office for its PromarkerEso, a blood test to rule out esophageal cancer caused by chronic acid reflux in patients, according to a Friday Australian bourse filing.
The granted patent provides intellectual property protection for PromarkerEso in Canada until Nov. 17, 2035, the filing said.